Back to top

Image: Bigstock

Allegiant (ALGT) Traffic and Load Factor Plummet In May

Read MoreHide Full Article

Allegiant Travel Company (ALGT - Free Report) reported bland traffic numbers for May, primarily due to weak air travel demand stemming from the COVID-19 pandemic. Traffic for scheduled service, measured in revenue passenger miles (RPMs), plunged 70.1% on a year-over-year basis to 32.7 million. Scheduled capacity, calculated in available seat miles (ASMs), also fell 47.2% to 690.6 million in the month.

Since the decline in traffic exceeded capacity reduction, load factor (percentage of seats filled with passengers) plunged 3630 basis points year over year to 47.3%.

The number of departures for scheduled service declined 48.8% on a year-over-year basis. However, average stage length (average distance flown per aircraft departure) climbed 1.5% to 856 miles in the same month. For the total system (including scheduled service and fixed fee contract), number of departures fell 49.1%, while the average stage length inched up 1.3% to 855 miles.

Zacks Ranks & Key Picks

Allegiant currently carries a Zacks Rank #3 (Hold).

A few better-ranked stocks in the Zacks Transportation sector are Air Lease Corporation (AL - Free Report) , Ryanair Holdings plc (RYAAY - Free Report) and Teekay Tankers Ltd. (TNK - Free Report) . All the stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Long-term earnings (three to five years) growth rate for Air Lease, Ryanair Holdings and Teekay Tankers is estimated at 3.1%, 20.5% and 3%, respectively.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

 

Published in